Literature DB >> 11676885

Spinal drug delivery.

T S Grabow1, D Derdzinski, P S Staats.   

Abstract

Clinicians currently base decisions regarding the use of intrathecal drug therapy for chronic pain on reports from uncontrolled and retrospective studies that fail to rely on standardized outcome measures. In this article, we summarize what is known about currently administered intrathecal therapies, including opioids, gamma-aminobutyric acid agonists, alpha-2 adrenoreceptor agonists, local anesthetics (sodium channel antagonists), calcium channel antagonists, miscellaneous agents, and drug combination therapy. In addition, we offer a brief look at novel approaches that may revolutionize intrathecal drug delivery.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11676885     DOI： 10.1007/s11916-001-0068-0

Source DB:  PubMed          Journal:  Curr Pain Headache Rep        ISSN： 1534-3081


  50 in total

1.  Intrathecal baclofen is analgesic in patients with chronic pain.

Authors:  R E Zuniga; C R Schlicht; S E Abram
Journal:  Anesthesiology       Date:  2000-03       Impact factor: 7.892

Review 2.  P2X receptors in sensory neurones.

Authors:  G Burnstock
Journal:  Br J Anaesth       Date:  2000-04       Impact factor: 9.166

3.  Current practices in intraspinal therapy--a survey of clinical trends and decision making.

Authors:  S J Hassenbusch; R K Portenoy
Journal:  J Pain Symptom Manage       Date:  2000-08       Impact factor: 3.612

4.  The cost of compensable low back pain.

Authors:  B S Webster; S H Snook
Journal:  J Occup Med       Date:  1990-01

5.  Long-term intrathecal administration of midazolam and clonidine.

Authors:  P A Borg; H J Krijnen
Journal:  Clin J Pain       Date:  1996-03       Impact factor: 3.442

6.  An A1-selective adenosine agonist abolishes allodynia elicited by vibration and touch after intrathecal injection.

Authors:  R Karlsten; T Gordh
Journal:  Anesth Analg       Date:  1995-04       Impact factor: 5.108

7.  Intrathecal, but not intravenous, clonidine reduces experimental thermal or capsaicin-induced pain and hyperalgesia in normal volunteers.

Authors:  J C Eisenach; D D Hood; R Curry
Journal:  Anesth Analg       Date:  1998-09       Impact factor: 5.108

8.  The control of severe cancer pain by continuous intrathecal infusion and patient controlled intrathecal analgesia with morphine, bupivacaine and clonidine.

Authors:  Paul S Tumber; Dermot R Fitzgibbon
Journal:  Pain       Date:  1998-12       Impact factor: 6.961

9.  [Chronic refractory pain in cancer patients. Value of the spinal injection of lysine acetylsalicylate. 60 cases].

Authors:  M Pellerin; F Hardy; A Abergel; D Boule; J H Palacci; P Babinet; L N Wingtin; J Glowinski; J F Amiot; D Mechali
Journal:  Presse Med       Date:  1987-09-19       Impact factor: 1.228

10.  Long-term intrathecal ziconotide therapy: a case study and discussion.

Authors:  P S Staats; F Luthardt; J Shipley; C Jackson; K Fischer
Journal:  Neuromodulation       Date:  2001-07
View more
  3 in total

1.  [Neurological complications and loss of efficacy with intrathecal pain therapy].

Authors:  D Kindler; C Maier; T Kagel; S Schulz; T Weiss; M Zenz
Journal:  Schmerz       Date:  2005-04       Impact factor: 1.107

Review 2.  Intrathecal analgesic drug therapy.

Authors:  Alan Farrow-Gillespie; Kimberly M Kaplan
Journal:  Curr Pain Headache Rep       Date:  2006-02

3.  A novel newborn rat kernicterus model created by injecting a bilirubin solution into the cisterna magna.

Authors:  Sijie Song; Ying Hu; Xianfang Gu; Feifei Si; Ziyu Hua
Journal:  PLoS One       Date:  2014-05-05       Impact factor: 3.240
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.